March 28, 2019
Chugai Pharmaceutical said on March 27 that risdiplam, an oral survival motor neuron-2 (SMN2) splicing modifier also known with the development code RG7916, earned orphan drug designation in Japan for an expected indication of spinal muscular atrophy (SMA). Global PII/III...read more